| scholarly article | Q13442814 |
| P2093 | author name string | Harsh Negi | |
| Prabhat Kosta | |||
| Sanvidhan G Suke | |||
| P2860 | cites work | Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics | Q24616751 |
| Gathering and exploring scientific knowledge in pharmacovigilance | Q28536855 | ||
| Postmarket drug surveillance without trial costs: discovery of adverse drug reactions through large-scale analysis of web search queries | Q28677138 | ||
| Novel data-mining methodologies for adverse drug event discovery and analysis | Q28681788 | ||
| Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies | Q29616299 | ||
| Monitoring vaccine safety during an influenza pandemic. | Q30358313 | ||
| Signal generation and clarification: use of case-control data. | Q30658394 | ||
| European surveillance of antimicrobial consumption (ESAC): data collection performance and methodological approach | Q30960100 | ||
| Application of an empiric Bayesian data mining algorithm to reports of pancreatitis associated with atypical antipsychotics | Q30967392 | ||
| Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment | Q31144283 | ||
| The impact of electronic medical records data sources on an adverse drug event quality measure | Q33535119 | ||
| Validation and validity of diagnoses in the General Practice Research Database: a systematic review | Q33588222 | ||
| Unsafe injections in the developing world and transmission of bloodborne pathogens: a review | Q33791766 | ||
| Payment of clinical research subjects | Q33865929 | ||
| Recognition, Investigation and Management of Acute Transfusion Reactions: Consensus guidelines for Oman | Q33982899 | ||
| Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group | Q34062887 | ||
| Pharmacovigilance for clinical trials in India: Current practice and areas for reform | Q35062790 | ||
| Assessing the impact of drug safety signals from the WHO database presented in 'SIGNAL': results from a questionnaire of National pharmacovigilance Centres | Q35178552 | ||
| The epidemiology of preventable adverse drug events: a review of the literature. | Q35199502 | ||
| Non-sedating antihistamine drugs and cardiac arrhythmias -- biased risk estimates from spontaneous reporting systems? | Q35803639 | ||
| Under-reporting of adverse drug reactions in general practice | Q36093893 | ||
| What is the role of the research ethics committee? Paternalism, inducements, and harm in research ethics. | Q36182486 | ||
| Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development | Q36294091 | ||
| The Vaccine Safety Datalink: immunization research in health maintenance organizations in the USA | Q36921494 | ||
| Pharmacovigilance: methods, recent developments and future perspectives | Q37181786 | ||
| Pharmacovigilance in Asia | Q37369668 | ||
| Quantitative signal detection using spontaneous ADR reporting | Q37439662 | ||
| A systematic literature review: prescribing indicators related to type 2 diabetes mellitus and cardiovascular risk management. | Q37644357 | ||
| European Medicines Agency support mechanisms fostering orphan drug development | Q37692188 | ||
| A model for the future conduct of pharmacovigilance | Q40602394 | ||
| A statistical methodology for postmarketing surveillance of adverse drug reaction reports | Q41408294 | ||
| Can adverse drug reactions be detected earlier? A comparison of reports by patients and professionals. | Q41966060 | ||
| Pharmacogenomics: the right drug to the right person | Q42589390 | ||
| H1N1 vaccine safety monitoring: beyond background rates | Q44032016 | ||
| Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. | Q45915951 | ||
| Exenatide and acute pancreatitis | Q46074007 | ||
| Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval. | Q46986240 | ||
| Reporting systems for rare side effects of non-narcotic analgesics in India. Problems and opportunities. | Q47416967 | ||
| Protecting human subjects from harm through improved risk judgments. | Q52499531 | ||
| Signal Selection and Follow-Up in Pharmacovigilance | Q63865885 | ||
| [Organization and results of drug vigilance in France] | Q72837697 | ||
| Pharmacogenomics: will the regulators approve? | Q74401500 | ||
| Use of pairwise marker combination and recursive partitioning in a pharmacogenetic genome-wide scan | Q80252475 | ||
| Adverse event detection in drug development: recommendations and obligations beyond phase 3 | Q81461912 | ||
| The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety | Q83289547 | ||
| P433 | issue | 2 | |
| P921 | main subject | India | Q668 |
| P304 | page(s) | e223 | |
| P577 | publication date | 2015-07-01 | |
| P1433 | published in | Online journal of public health informatics | Q27723307 |
| P1476 | title | Role of Pharmacovigilance in India: An overview | |
| P478 | volume | 7 |
| Q37266523 | A Retrospective Analysis of Reporting of Adverse Drug Reactions in a Tertiary Care Teaching Hospital: One Year Survey |
| Q90743882 | A multiparametric organ toxicity predictor for drug discovery |
| Q38614914 | Adverse drug reactions reporting by undergraduate medical students in a tertiary care teaching hospital of India: Content and quality analysis in comparison to physician reporting. |
| Q97524511 | Effect of educational intervention on awareness of pharmacovigilance among medical undergraduates in a tertiary care teaching hospital |
| Q26752265 | Health Professionals' Knowledge, Attitudes and Practices about Pharmacovigilance in India: A Systematic Review and Meta-Analysis |
| Q26741871 | Reporting of adverse events for marketed drugs: Need for strengthening safety database |
Search more.